HC Wainwright Issues Negative Outlook for PLX Earnings

Key Points

• HC Wainwright cut its Q1 2026 EPS estimate for Protalix to ($0.01) from $0.04 while maintaining a Buy rating and a $12 price target, and also issued Q2, Q3 and FY2027 EPS estimates.
• Shares opened at $2.14 and were down about 4%; the company has a market cap of $172.4M, a negative P/E (~-16.46), and a 52‑week range of $1.32–$3.19.
• Multiple institutions recently added small positions in PLX, with overall institutional ownership at roughly 16.53%.

Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Research analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for shares of Protalix BioTherapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.01) per share for the quarter, down from their prior forecast of $0.04. HC Wainwright currently has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics' Q2 2026 earnings at $0.27 EPS, Q3 2026 earnings at ($0.01) EPS and FY2027 earnings at $0.14 EPS.

Protalix BioTherapeutics Stock Down 4.0%

Shares of NYSE:PLX opened at $2.14 on Monday. The company has a market cap of $172.42 million, a P/E ratio of -16.46 and a beta of -0.26. The business has a fifty day simple moving average of $2.61 and a 200-day simple moving average of $2.21. Protalix BioTherapeutics has a 52 week low of $1.32 and a 52 week high of $3.19.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PLX. R Squared Ltd purchased a new position in shares of Protalix BioTherapeutics during the 4th quarter worth about $26,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Protalix BioTherapeutics in the second quarter valued at approximately $27,000. SG Americas Securities LLC acquired a new position in Protalix BioTherapeutics during the fourth quarter worth approximately $31,000. Bank of America Corp DE increased its position in Protalix BioTherapeutics by 364,766.7% during the second quarter. Bank of America Corp DE now owns 21,892 shares of the company's stock worth $32,000 after purchasing an additional 21,886 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Protalix BioTherapeutics during the fourth quarter worth approximately $34,000. Institutional investors and hedge funds own 16.53% of the company's stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics NYSE: PLX is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix's core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company's first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.